DT-Web

DB00952 - Naratriptan


Identification
Name Naratriptan
Accession Number DB00952 (APRD00220)
Type small molecule
Description Naratriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 335.464
Groups approved
Monoisotopic Weight 335.166747749
Pharmacology
Indication For the acute treatment of migraine attacks with or without aura in adults.
Mechanism of action Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
Absorption Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.
Protein binding 28%-31% (over the concentration range of 50 to 1000 ng/mL)
Biotransformation Primarily hepatic. In vitro, naratriptan is metabolized by a wide range of cytochrome P450 isoenzymes into a number of inactive metabolites.
Route of elimination Not Available
Toxicity Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Citalopram Increased risk of CNS adverse effects
Desvenlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Dihydroergotamine Naratriptan, a serotonin 5-HT1D receptor agonists, may increase the vasoconstricting effect of dihydroergotamine. Concomitant use of these two agents within 24 hours is contraindicated.
Dihydroergotoxine Possible severe and prolonged vasocontriction
Ergonovine Possible severe and prolonged vasocontriction
Ergotamine Possible severe and prolonged vasoconstriction.
Escitalopram Increased risk of CNS adverse effects
Fluoxetine Increased risk of CNS adverse effects
Fluvoxamine Increased risk of CNS adverse effects
Isocarboxazid The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome.
Methylergonovine Possible severe and prolonged vasocontriction
Methysergide Possible severe and prolonged vasoconstriction.
Nefazodone Increased risk of CNS adverse effects
Paroxetine Increased risk of CNS adverse effects
Phenelzine The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome.
Sertraline Increased risk of CNS adverse effects
Sibutramine Increased risk of CNS adverse effects
Tramadol Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Tranylcypromine Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
Trazodone Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Trimipramine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Venlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Vilazodone Increased risk of serotonin syndrome
Zolmitriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and naratriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Food Interactions
  • Take without regard to meals.

Targets


5-hydroxytryptamine 1D receptor
Name 5-hydroxytryptamine 1D receptor
Gene Name HTR1D
Pharmacological action yes
Actions agonist
References
  • Hargreaves RJ, Shepheard SL: Pathophysiology of migraine--new insights. Can J Neurol Sci. 1999 Nov;26 Suppl 3:S12-9. - Pubmed
  • Donaldson C, Boers PM, Hoskin KL, Zagami AS, Lambert GA: The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology. 2002 Mar;42(3):374-85. - Pubmed
  • Pauwels PJ, Colpaert FC: Selective antagonism of human 5-HT1D and 5-HT1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935. Eur J Pharmacol. 1996 Apr 4;300(1-2):141-5. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
  • Akin D, Onaran HO, Gurdal H: Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. Br J Pharmacol. 2002 May;136(2):171-6. - Pubmed
  • Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9. - Pubmed
  • Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109. - Pubmed
  • Johnston MM, Rapoport AM: Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. - Pubmed
  • Dulli DA: Naratriptan: an alternative for migraine. Ann Pharmacother. 1999 Jun;33(6):704-11. - Pubmed
  • Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. - Pubmed
  • Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. - Pubmed
  • Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. - Pubmed
DTHybrid score 0.4307
5-hydroxytryptamine 1B receptor
Name 5-hydroxytryptamine 1B receptor
Gene Name HTR1B
Pharmacological action yes
Actions agonist
References
  • Akin D, Onaran HO, Gurdal H: Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. Br J Pharmacol. 2002 May;136(2):171-6. - Pubmed
  • Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9. - Pubmed
  • Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109. - Pubmed
  • Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
  • Johnston MM, Rapoport AM: Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. - Pubmed
  • Dulli DA: Naratriptan: an alternative for migraine. Ann Pharmacother. 1999 Jun;33(6):704-11. - Pubmed
  • Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. - Pubmed
  • Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. - Pubmed
  • Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. - Pubmed
DTHybrid score 0.4578
5-hydroxytryptamine 1F receptor
Name 5-hydroxytryptamine 1F receptor
Gene Name HTR1F
Pharmacological action yes
Actions agonist
References
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
  • Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9. - Pubmed
  • Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. - Pubmed
  • Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. - Pubmed
  • Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. - Pubmed
  • Goadsby PJ, Classey JD: Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8. - Pubmed
  • Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. - Pubmed
DTHybrid score 0.4103
5-hydroxytryptamine 1A receptor
Name 5-hydroxytryptamine 1A receptor
Gene Name HTR1A
Pharmacological action yes
Actions agonist
References
  • Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109. - Pubmed
  • Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. - Pubmed
DTHybrid score 0.4011

Enzymes


Amine oxidase [flavin-containing] A
Name Amine oxidase [flavin-containing] A
Gene Name MAOA
Actions substrate
References
  • Millson DS, Tepper SJ, Rapoport AM: Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404. - Pubmed
DTHybrid score 0.5686

Predictions


Id Partner name Gene Name Score
3939 Amine oxidase [flavin-containing] B MAOB 0.1689
4200 Cytochrome P450 1A2 CYP1A2 0.1527
502 5-hydroxytryptamine 2A receptor HTR2A 0.124
318 Alpha-2A adrenergic receptor ADRA2A 0.1225
4119 Cytochrome P450 2D6 CYP2D6 0.1115
831 D(2) dopamine receptor DRD2 0.1087
436 5-hydroxytryptamine 2B receptor HTR2B 0.1035
629 Alpha-2B adrenergic receptor ADRA2B 0.1009
4512 Cytochrome P450 3A4 CYP3A4 0.1003
378 Alpha-2C adrenergic receptor ADRA2C 0.0965
590 5-hydroxytryptamine 2C receptor HTR2C 0.0953
23 D(1A) dopamine receptor DRD1 0.0937
638 D(3) dopamine receptor DRD3 0.0925
432 D(4) dopamine receptor DRD4 0.0856
1588 Multidrug resistance protein 1 ABCB1 0.0774
716 5-hydroxytryptamine 7 receptor HTR7 0.0743
556 Alpha-1A adrenergic receptor ADRA1A 0.0742
163 D(1B) dopamine receptor DRD5 0.0736
632 Alpha-1B adrenergic receptor ADRA1B 0.0583
193 Beta-1 adrenergic receptor ADRB1 0.0567
528 5-hydroxytryptamine 1E receptor HTR1E 0.0522
766 Beta-2 adrenergic receptor ADRB2 0.0504
6016 Cytochrome P450 2C19 CYP2C19 0.0498
824 Sodium-dependent serotonin transporter SLC6A4 0.0468
4757 Cytochrome P450 2C9 CYP2C9 0.037
713 Sodium-dependent dopamine transporter SLC6A3 0.0354
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0335
789 Alpha-1D adrenergic receptor ADRA1D 0.032
492 Histamine H1 receptor HRH1 0.0312
4118 Cytochrome P450 3A5 CYP3A5 0.0306
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0292
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0286
1256 5-hydroxytryptamine 6 receptor HTR6 0.0284
6107 Cytochrome P450 3A7 CYP3A7 0.0278
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0275
1517 Beta-3 adrenergic receptor ADRB3 0.0272
6013 Cytochrome P450 2E1 CYP2E1 0.0262
341 5-hydroxytryptamine 3 receptor HTR3A 0.0251
103 Muscarinic acetylcholine receptor M1 CHRM1 0.0248
5718 Cytochrome P450 2A6 CYP2A6 0.0244
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0233
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0226
94 5-hydroxytryptamine 4 receptor HTR4 0.0208
274 Muscarinic acetylcholine receptor M5 CHRM5 0.0203
450 Muscarinic acetylcholine receptor M4 CHRM4 0.0198
6145 Solute carrier family 22 member 1 SLC22A1 0.0182
131 Synaptic vesicular amine transporter SLC18A2 0.0179
51 Muscarinic acetylcholine receptor M3 CHRM3 0.0177
617 Muscarinic acetylcholine receptor M2 CHRM2 0.0173
734 D1 dopamine receptor-interacting protein calcyon CALY 0.0166
20 Prostaglandin G/H synthase 1 PTGS1 0.0161
4924 Cytochrome P450 2C8 CYP2C8 0.0157
3810 Catechol O-methyltransferase COMT 0.0147
587 Serum albumin ALB 0.0129
6144 Solute carrier family 22 member 2 SLC22A2 0.0122
5698 Riboflavin synthase alpha chain ribE 0.0105
408 Riboflavin kinase RFK 0.0101
146 Androgen receptor AR 0.0089
3811 Cytochrome P450 19A1 CYP19A1 0.0088
6024 Cytochrome P450 1A1 CYP1A1 0.0077
654 Flavin reductase BLVRB 0.0075
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.0071
3917 Methylenetetrahydrofolate reductase MTHFR 0.0066
6147 Solute carrier family 22 member 3 SLC22A3 0.0065
6030 Cytochrome P450 2B6 CYP2B6 0.0065
1656 CYP2B protein CYP2B 0.0064
1757 Myeloperoxidase MPO 0.0059
6106 Cytochrome P450 2C18 CYP2C18 0.0054
847 Mu-type opioid receptor OPRM1 0.0053
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0052
164 Histamine H4 receptor HRH4 0.0048
118 Organic cation/carnitine transporter 2 SLC22A5 0.0047
124 Histamine H2 receptor HRH2 0.0046
6031 Cytochrome P450 3A43 CYP3A43 0.0042
3913 Glutamic acid decarboxylase GAD65 0.0042
1636 Trace amine-associated receptor 1 TAAR1 0.0041
1729 Solute carrier family 22 member 6 SLC22A6 0.0041
1898 Cytochrome P450 1B1 CYP1B1 0.004
1483 Membrane copper amine oxidase AOC3 0.0039
6014 Cytochrome P450 2A13 CYP2A13 0.0036
735 Alanine aminotransferase 1 GPT 0.0034
3904 Alanine aminotransferase 2 GPT2 0.0034
6164 POU domain, class 5, transcription factor 1 POU5F1 0.0032
474 Acetylcholinesterase ACHE 0.003
280 4-aminobutyrate aminotransferase, mitochondrial ABAT 0.0028
153 Dopamine beta-hydroxylase DBH 0.0025
833 Organic cation/carnitine transporter 1 SLC22A4 0.0024
6133 Sodium channel subunit beta-2 SCN2B 0.002
6134 Sodium channel subunit beta-3 SCN3B 0.002
6132 Sodium channel subunit beta-1 SCN1B 0.002
6135 Sodium channel subunit beta-4 SCN4B 0.002
6127 Carbonic anhydrase-related protein CA8 0.002
6129 Carbonic anhydrase-related protein 11 CA11 0.002
6128 Carbonic anhydrase-related protein 10 CA10 0.002
6082 Neuronal acetylcholine receptor subunit beta-3 CHRNB3 0.002
6080 Neuronal acetylcholine receptor subunit alpha-5 CHRNA5 0.002
948 Neuronal acetylcholine receptor subunit beta-2 CHRNB2 0.002
3803 Sodium channel protein type 3 subunit alpha SCN3A 0.0018
4097 Neuronal acetylcholine receptor subunit alpha-9 CHRNA9 0.0018
6130 Carbonic anhydrase 13 CA13 0.0018
6081 Neuronal acetylcholine receptor subunit alpha-6 CHRNA6 0.0018
6124 Carbonic anhydrase 5B, mitochondrial CA5B 0.0018
215 Sodium channel protein type 11 subunit alpha SCN11A 0.0017
6131 Carbonic anhydrase 14 CA14 0.0017
6078 Neuronal acetylcholine receptor subunit beta-4 CHRNB4 0.0017
6100 BDNF/NT-3 growth factors receptor NTRK2 0.0016
3802 Sodium channel protein type 2 subunit alpha SCN2A 0.0016
6122 Carbonic anhydrase 3 CA3 0.0016
776 Bile salt export pump ABCB11 0.0016
6123 Carbonic anhydrase 5A, mitochondrial CA5A 0.0015
6079 Neuronal acetylcholine receptor subunit alpha-3 CHRNA3 0.0015
3804 Sodium channel protein type 4 subunit alpha SCN4A 0.0015
1995 Sodium channel protein type 9 subunit alpha SCN9A 0.0015
458 Neuronal acetylcholine receptor subunit alpha-10 CHRNA10 0.0015
756 Sex hormone-binding globulin SHBG 0.0015
3007 Carbonic anhydrase 12 CA12 0.0014
4205 Carbonic anhydrase 9 CA9 0.0014
3923 Cholinesterase BCHE 0.0014
6141 Sodium/bile acid cotransporter SLC10A1 0.0014
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.0014
15 Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I 0.0013
6126 Carbonic anhydrase 7 CA7 0.0013
158 Sodium channel protein type 1 subunit alpha SCN1A 0.0013
1618 High affinity nerve growth factor receptor NTRK1 0.0013
535 Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G 0.0013
6098 Potassium voltage-gated channel subfamily D member 2 KCND2 0.0012
6099 Potassium voltage-gated channel subfamily D member 3 KCND3 0.0012
1086 Potassium voltage-gated channel subfamily KQT member 2 KCNQ2 0.0012
964 Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H 0.0012
813 Neuronal acetylcholine receptor subunit alpha-2 CHRNA2 0.0011
6143 Solute carrier family 22 member 7 SLC22A7 0.0011
4095 Neuronal acetylcholine receptor subunit alpha-7 CHRNA7 0.0011
947 Neuronal acetylcholine receptor subunit alpha-4 CHRNA4 0.0011
6020 Aldehyde oxidase AOX1 0.0011
592 Carbonic anhydrase 4 CA4 0.0011
295 Carbonic anhydrase 1 CA1 0.001
6142 Solute carrier family 22 member 8 SLC22A8 0.001
858 Potassium voltage-gated channel subfamily A member 1 KCNA1 0.001
220 Sodium channel protein type 5 subunit alpha SCN5A 0.001
4439 Ferredoxin reductase bphA4 0.0009
4486 Phenol 2-hydroxylase component B pheA2 0.0009
4477 Dihydrolipoyl dehydrogenase lpdV 0.0009
5077 Dihydrolipoyl dehydrogenase Not Available 0.0009
5117 Dihydrolipoyl dehydrogenase lpd 0.0009
5078 Amine oxidase, flavin-containing PSPTO1126 0.0009
5095 Putidaredoxin reductase camA 0.0009
5122 Mersacidin decarboxylase mrsD 0.0009
526 Thioredoxin reductase trxB 0.0009
3767 Thioredoxin reductase trxB 0.0009
5114 Putative acyl-CoA dehydrogenase TT_C0779 0.0009
5107 Alkyl hydroperoxide reductase subunit F ahpF 0.0009
5118 Alkyl hydroperoxide reductase subunit F ahpF 0.0009
5109 Outer membrane protein p64k or PM-6 m-6 0.0009
5097 PROBABLE DIHYDROLIPOAMIDE DEHYDROGENASE LPDA lpdA 0.0009
5115 FkbI fkbI 0.0009
3133 UDP-galactopyranose mutase glf 0.0009
5099 UDP-galactopyranose mutase glf 0.0009
1329 Apoptosis-inducing factor 1, mitochondrial AIFM1 0.0009
5083 Cryptochrome DASH cry 0.0009
5100 Gamma-aminobutyrate metabolism dehydratase/isomerase abfD 0.0009
5102 4-cresol dehydrogenase [hydroxylating] flavoprotein subunit pchF 0.0009
3763 5,10-methylenetetrahydrofolate reductase metF 0.0009
3918 5,10-methylenetetrahydrofolate reductase MTHFR 0.0009
5094 5,10-methylenetetrahydrofolate reductase metF 0.0009
5081 L-aspartate oxidase nadB 0.0009
5111 Phenylacetone monooxygenase pamO 0.0009
1410 Oxidoreductase HSD17B6 0.0008
4725 Oxidoreductase Not Available 0.0008
5124 Oxidoreductase Not Available 0.0008
5112 Benzoate 1,2-dioxygenase electron transfer component benC 0.0008
357 Carbonic anhydrase 2 CA2 0.0008
467 Delta-type opioid receptor OPRD1 0.0008
696 Kappa-type opioid receptor OPRK1 0.0008
4440 NADH peroxidase npr 0.0008
3102 Flavohemoprotein hmp 0.0008
4969 Flavohemoprotein hmp 0.0008
327 Glutathione reductase gor 0.0007
5110 Glutathione reductase GR2 0.0007
5091 UDP-N-acetylenolpyruvoylglucosamine reductase murB 0.0007
5093 UDP-N-acetylenolpyruvoylglucosamine reductase murB 0.0007
3594 Deoxyribodipyrimidine photo-lyase phr 0.0007
5079 Deoxyribodipyrimidine photo-lyase phrB 0.0007
5080 Deoxyribodipyrimidine photo-lyase phr 0.0007
5072 N,N-dimethylglycine oxidase dmg 0.0007
178 NADH-cytochrome b5 reductase 3 CYB5R3 0.0007
812 Dihydrolipoyl dehydrogenase, mitochondrial DLD 0.0007
2470 Pyruvate oxidase pox5 0.0007
5073 Ferredoxin--NADP reductase petH 0.0007
5076 Ferredoxin--NADP reductase fpr 0.0007
5119 Ferredoxin--NADP reductase petH 0.0007
5121 Ferredoxin--NADP reductase fpr 0.0007
5075 Sulfite reductase [NADPH] flavoprotein alpha-component cysJ 0.0007
440 Isovaleryl-CoA dehydrogenase, mitochondrial IVD 0.0007
3506 Glutaryl-CoA dehydrogenase, mitochondrial GCDH 0.0007
667 Acyl-CoA dehydrogenase family member 8, mitochondrial ACAD8 0.0007
5003 Acyl-CoA dehydrogenase, short-chain specific Not Available 0.0007
2268 Cholesterol oxidase choB 0.0007
2822 Cholesterol oxidase choA 0.0007
2526 NADPH-ferredoxin reductase fprA fprA 0.0007
6639 Peroxisomal acyl-coenzyme A oxidase 1 ACOX1 0.0007
3247 2-oxopropyl-CoM reductase, carboxylating xecC 0.0007
126 D-lactate dehydrogenase dld 0.0007
3545 D-lactate dehydrogenase Not Available 0.0007
4510 D-lactate dehydrogenase ldhA 0.0007
605 Fumarate reductase flavoprotein subunit frdA 0.0007
2709 Fumarate reductase flavoprotein subunit SO_0970 0.0007
3673 Fumarate reductase flavoprotein subunit fccA 0.0007
4912 Fumarate reductase flavoprotein subunit ifcA 0.0007
6549 Fumarate reductase flavoprotein subunit frdA 0.0007
3185 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial ACADM 0.0007
3254 Bifunctional protein putA [Includes: Proline dehydrogenase putA 0.0007
2893 Glycine oxidase thiO 0.0007
839 Short-chain specific acyl-CoA dehydrogenase, mitochondrial ACADS 0.0006
2769 P-hydroxybenzoate hydroxylase pobA 0.0006
2809 P-hydroxybenzoate hydroxylase pobA 0.0006
3573 2,4-dienoyl-CoA reductase [NADPH] fadH 0.0006
2567 Thymidylate synthase thyX thyX 0.0006
2823 Trypanothione reductase TPR 0.0006
6645 D-amino-acid oxidase DAO 0.0006
3610 Thioredoxin reductase 1, cytoplasmic TXNRD1 0.0006
2380 Monomeric sarcosine oxidase soxA 0.0006
1302 Dihydropyrimidine dehydrogenase [NADP+] DPYD 0.0005
243 Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 0.0005
714 Glutathione reductase, mitochondrial GSR 0.0005
4120 NADPH--cytochrome P450 reductase POR 0.0005
2157 NAD(P)H dehydrogenase [quinone] 1 NQO1 0.0005
76 Nitric-oxide synthase, brain NOS1 0.0005
3947 Xanthine dehydrogenase/oxidase XDH 0.0004
↑